一种素抗原疫苗用于治疗自身免疫性关节炎
Xu Jin1, Tianya Dong2, Qian Wang3
1Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
Science bulletin
|August 17, 2024
概括
一种新的素抗原 (citAg) 疫苗在治疗类风湿性关节炎 (RA) 方面表现有前途. 这种疫苗减少了自身免疫反应和炎症,有可能恢复RA患者的免疫平衡.
科学领域:
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
- 疫苗开发 疫苗开发
背景情况:
- 类风湿性关节炎 (RA) 是一种由遗传和环境因素影响的炎症性自身免疫性疾病.
- 抗原特异性疗法旨在恢复RA的免疫耐受性,而无需广泛的免疫抑制.
- 抗原的素化可以增强其免疫性,有助于RA的自身免疫反应.
研究的目的:
- 评估一个素抗原 (citAg) 疫苗在改善类风湿性关节炎的治疗潜力.
- 在关节炎模型中研究citAg疫苗对免疫细胞群和细胞因子概况的影响.
- 探索citAg疫苗对免疫谱系调节的影响,特别是V(D) J重组.
主要方法:
- 在原诱导性关节炎模型中使用素抗原 (citAg) 疫苗.
- 对T助手1 (Th1) 和T助手17 (Th17) 细胞种群的评估.
- 预炎性细胞因子的量化,包括互白素-6 (IL-6) 和瘤坏死因子-α (TNF-α).
- 对抗原召回反应和B细胞受体测序的分析,以评估免疫谱的恢复.
主要成果:
- 这种CitAg疫苗显著改善了原诱导的关节炎.
- 接种疫苗导致Th1和Th17细胞反应降低.
- 促炎性细胞因子水平 (IL-6,TNF-α) 的下调.
- 抗原召回反应被抑制,V(D) J重组正常化,这表明免疫谱系的恢复.
结论:
- 素抗原 (citAg) 疫苗显示了对类风湿性关节炎的治疗潜力.
- 该疫苗通过减少特定的自身免疫T细胞反应和炎症性细胞因子生产来起作用.
- 通过调节免疫细胞活性和V(D) J重组,citAg疫苗可能会恢复免疫平衡.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Autoimmune Disorders
398
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
398
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493


